Eyes on neu­ro break­throughs, new­com­er Bio­mat­ics adds biotech vets and $300M with sec­ond fund

Less than two years af­ter a pair of Gates Foun­da­tion vets — Boris Nikolic and Julie Sun­der­land — got start­ed with their first ven­ture fund at Bio­mat­ics fo­cused on the in­ter­sec­tion of health­care and tech­nol­o­gy, they’re back with their sec­ond fund.

And this time they’re go­ing deep­er.

While the first fund de­liv­ered $250 mil­lion that was used to back the neu­ro teams at De­nali, Black­Thorn Ther­a­peu­tics, along with Grail and oth­er high-pro­file tech ven­tures grab­bing head­lines in the in­dus­try, this sec­ond fund has upped the ante to $300 mil­lion. That fast growth un­der­scores the fa­vor­able view their in­vestors have in this sec­tor, as well as the go-go at­mos­phere in new com­pa­ny cre­ation that has grabbed the world’s at­ten­tion in 2018.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER